Trials / Completed
CompletedNCT00743964
Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)
A Randomized Phase II Study of Combination Chemotherapy With Epirubicin , Cisplatin and Capecitabine (ECX) or Cisplatin and Capecitabine (CX) in Advanced Gastric Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 75 Years
- Healthy volunteers
- Not accepted
Summary
Recently, 3-drug (ECX) and 2-drug (CX) combination chemotherapy involving capecitabine showed promising results in randomized clinical trials for advanced gastric cancer (AGC). The objective of the study is to evaluate the safety and activity of ECX and CX combination chemotherapy given as first-line therapy for AGC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epirubicin | Epirubicin 50 mg/m2 iv on day 1 |
| DRUG | Cisplatin, capecitabine | Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14. |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2008-08-29
- Last updated
- 2010-01-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00743964. Inclusion in this directory is not an endorsement.